Impact of different low-dose ritonavir regimens on lipids, CD36, and adipophilin expression

Clinical Pharmacology and Therapeutics

Volumn 85, Issue 4, 2009, Pages 375-378

  Collot Teixeira, S ^a   De Lorenzo, F ^b   Waters, L ^c   Fletcher, C ^c   Back, D ^d   Mandalia, S ^c   Pozniak, A ^c   Yilmaz, S ^a   McGregor, J L ^a,e   Gazzard, B ^c   Boffito, M ^c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b CHELSEA AND WESTMINSTER HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^c CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^d UNIVERSITY OF LIVERPOOL   (United Kingdom)

^e INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOPHILIN; CD36 ANTIGEN; CD40 LIGAND; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RITONAVIR; TRIACYLGLYCEROL;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG BLOOD LEVEL; FEMALE; GENE EXPRESSION; HUMAN; HUMAN EXPERIMENT; LOW DRUG DOSE; MALE; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIDE EFFECT; VASCULITIS;

ADULT; ANTIGENS, CD36; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; GENE EXPRESSION REGULATION; HUMANS; LIPIDS; MALE; MIDDLE AGED; PEPTIDES; RITONAVIR; YOUNG ADULT;

EID: 62649112895     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2008.243     Document Type: Article

References (27)

1. Gazzard, B. et al. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006). HIV Med. 7, 487-503 (2006).
2. Alberti, K.G., Zimmet, P. & Shaw, J. Metabolic syndrome - a new world-wide definition. A Consensus Statement From the International Diabetes Federation. Diabet. Med. 23, 469-480 (2006).
3. Hanson, R.L., Imperatore, G., Bennett, P.H. & Knowler, W.C. Components of the "metabolic syndrome" and incidence of type 2 diabetes. Diabetes 51, 3120-3127 (2002).
4. Mallewa, J.E. et al. HIV-associated lipodystrophy: a review of underlying mechanisms and therapeutic options. J. Antimicrob. Chemother. 62, 648-660 (2008).
5. Lundgren, J.D. et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS 22, F17-F24 (2008).
6. Sabin, C.A. et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 371, 1417-1426 (2008).
7. De Lorenzo, F., Collot-Teixeira, S., Boffito, M., Feher, M., Gazzard, B. & McGregor, J.L. Risk of accelerated coronary heart diseases in HIV-infected patients: can it be prevented? Curr. Med. Chem. 15, 2991-2999 (2008).
8. Carpenter, C.C. et al. Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA. JAMA 276, 146-154 (1996).
9. Gatti, G. et al. The relationship between ritonavir plasma levels and side-effects: implications for therapeutic drug monitoring. AIDS 13, 2083-2089 (1999).
10. Di Perri, G., Del Bravo, P. & Concia, E. HIV-protease inhibitors. N. Engl. J. Med. 339, 773-774; author reply 4 (1998).
11. Shafran, S.D., Mashinter, L.D. & Roberts, S.E. The effect of low-dose ritonavir monotherapy on fasting serum lipid concentrations. HIV Med. 6, 421-425 (2005).
12. Umeh, O. et al. Sex differences in lopinavir/ritonavir soft gel capsule pharmacokinetics among HIV-infected females and males. 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, 25-28 February 2007. Abstract 786.
13. Sekar, V., Ryan, R., Schaible, D., Mazikewich, A. & Mrus, J.E. Pharmacokinetic profile of darunavir (DRV) co-administered with low-dose ritonavir (DRV/r) in treatment-experienced women and men with HIV infection: 4-week analysis in a substudy of the GRACE (Gender, Race, and Clinical Experience) study. 9th International Workshop on Clinical Pharmacology of HIV Therapy, New Orleans, LA, 7-8 April 2008.
14. Henn, V. et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 391, 591-594 (1998).
15. Kornbluth, R.S. The emerging role of CD40 ligand in HIV infection. J. Leukoc. Biol. 68, 373-382 (2000).
16. Collot-Teixeira, S., Martin, J., McDermott-Roe, C., Poston, R. & McGregor, J.L. CD36 and macrophages in atherosclerosis. Cardiovasc. Res. 75, 468-477 (2007).
17. Dressman, J. et al. HIV protease inhibitors promote atherosclerotic lesion formation independent of dyslipidemia by increasing CD36-dependent cholesteryl ester accumulation in macrophages. J. Clin. Invest. 111, 389-397 (2003).
18. Munteanu, A., Zingg, J.M., Ricciarelli, R. & Azzi, A. CD36 overexpression in ritonavir-treated THP-1 cells is reversed by alpha-tocopherol. Free Radic. Biol. Med. 38, 1047-1056 (2005).
19. Serghides, L., Nathoo, S., Walmsley, S. & Kain, K.C. CD36 deficiency induced by antiretroviral therapy. AIDS 16, 353-358 (2002).
20. Larigauderie, G. et al. Adipophilin enhances lipid accumulation and prevents lipid efflux from THP-1 macrophages: potential role in atherogenesis. Arterioscler. Thromb. Vasc. Biol. 24, 504-510 (2004).
21. Hui, D.Y. Effects of HIV protease inhibitor therapy on lipid metabolism. Prog. Lipid Res. 42, 81-92 (2003).
22. Fauvel, J. et al. An interaction between apo C-III variants and protease inhibitors contributes to high triglyceride/low HDL levels in treated HIV patients. AIDS 15, 2397-2406 (2001).
23. Noursadeghi, M. & Miller, R.F. Clinical value of C-reactive protein measurements in HIV-positive patients. Int. J. STD AIDS 16, 438-441 (2005).
24. Holmberg, S.D. et al. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 360, 1747-1748 (2002).
25. Friis-Møller, N. et al. Cardiovascular disease risk factors in HIV patients-association with antiretroviral therapy. Results from the DAD study. AIDS 17, 1179-1193 (2003).
26. Law, M. et al. Modelling the 3-year risk of myocardial infarction among participants in the Data Collection on Adverse Events of Anti-HIV Drugs (DAD) study. HIV Med. 4, 1-10 (2003).
27. Dickinson, L., Robinson, L., Tjia, J., Khoo, S. & Back, D. Simultaneous determination of HIV protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir in human plasma by high-performance liquid chromatography-tandem mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 829, 82-90 (2005).